MK0524A (laropiprant/niacin) in Primary Hypercholesterolemia/Mixed Hyperlipidemia
Hypercholesterolemia · Hyperlipidemia
Enrolment: 646 · Results not recorded
Loading the evidence…
Nutraceutical
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Hypercholesterolemia · Hyperlipidemia
Enrolment: 646 · Results not recorded
Hypercholesterolemia
Enrolment: 1220 · Results not recorded
Hypercholesterolemia · Hyperlipidemia
Enrolment: 1300 · Results not recorded
Impaired Glucose Tolerance
Enrolment: 50 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Pancreatic ischaemia by occlusion of both the gastroduodenal and splenic arteries for 120 min followed by 240 min reperfusion
Niacin pre-treatment reduced pancreatic and remote lung injury, attenuated pulmonary oxidative stress and inflammation, protected pulmonary barrier function and restored SIRT1 mRNA expression relative to untreated ischaemia-reperfusion animals.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
Model: spinal cord injury in mice, with in vitro M1 macrophage and oligodendrocyte precursor cell co-cultures
Niacin activation of the HCA2 receptor shifted macrophages from an M1 to M2 phenotype, promoted oligodendrocyte myelin binding protein expression, reduced demyelination and neurofilament loss, and improved locomotor recovery after spinal cord injury in mice.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.